HIV Negative and HIV Prevention

CID 0702 - Apheresis procedures to obtain leukocytes from HIV negative subjects

  • Question: Samples used as negative control for exploring new methods of activating resting HIV infected cells in laboratory
  • Population: must be HIV negative and > 18 years of age
  • Duration: up to 3 years
  • Contact: Blair Turner 919-966-7747

HPTN 069 NEXT PREP: Novel Exploration of Therapeutics for PREP: A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC + FTC), Maraviroc + Tenofovir disoproxil fumerate (MVC + TDF), or Tenofovir disoproxil fumerate + Emtricitabine (TDF + FTC) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission in at-Risk Women

  • Population: HIV-uninfected at-risk MSM and at-risk women recruited from sites in the US
  • Medication: maraviroc (MVC) 300 mg, emtricitabine (FTC) 200 mg, tenofovir disoproxil fumerate (TDF) 300 mg, and matching placebos
  • Duration: 1 year
  • Contact: Donna Pittard 919-843-6512